Breaking News

Moneypox Cases Confirmed in England

June 11, 2021 • 4:39 pm CDT
(Vax Before Travel)

Denmark-based Bavarian Nordic A/S announced today that the Company was recently engaged by Public Health England (PHE) and the Medicines and Health Products Regulatory Agency to supply IMVANEX® smallpox vaccine in response to new cases of monkeypox in the UK.

Two related cases were admitted to a hospital in Liverpool, England.

One was most likely infected in Africa, where the family arrived from a few days before the onset of disease, and a sibling case most likely infected on UK soil by the first case. 

Monkeypox is a rare but serious disease, which is endemic in Central and West Africa. Although it is less severe with an estimated fatality rate of up to 10%, the disease is quite similar to human smallpox, says PHE.

Paul Chaplin, President and CEO of Bavarian Nordic, commented in a press statement, “We are pleased to assist PHE rapidly in such an emergency. Vaccination is a critical measure to prevent and control the spread of diseases globally. Governments have an essential role in preparing for outbreaks by stockpiling vaccines and treatments so that they are readily available in events like this."

Bavarian Nordic previously delivered IMVANEX to PHE in connection with the first human cases of monkeypox in the UK in 2018 and later in 2019.

IMVANEX (MVA-BN) is approved by the European Commission for active immunization against smallpox and has also received approval for monkeypox by the U.S. Food and Drug Administration (JYNNEOS) and Health Canada, the only vaccine approved for this indication in these territories.

On May 7, 2021, Bavarian Nordic confirmed the U.S. Biomedical Advanced Research and Development Authority had exercised the final $12 million option under the $202 million order for JYNNEOS awarded in April 2020.

Bavarian Nordic (OMX: BAVA) is a fully integrated vaccines company focused on developing, manufacturing, and commercializing life-saving vaccines.